Immunoregulation of Periodontal Disease

Periodontal Disease Clinical Trial

Official title:

Immunoregulation of Periodontal Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00702429
• Other study ID #: 2007-A00632-51
• Status: Completed
• Phase: N/A
• First received: June 18, 2008
• Last updated: August 27, 2014
• Start date: August 2008
• Est. completion date: July 2010

Study information

• Verified date: August 2014
• Source: Assistance Publique Hopitaux De Marseille
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

Our design is to test in hospital practice a selection of immune parameters that could assess the pathophysiology and progression of periodontal lesions.

Description:

These parameters will be measured in 25 healthy volunteers and 25 moderate-to severe periodontal disese patients. Phagocytes will be tested phenotypically and functionally, both ex vivo and in vitro.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: July 2010
• Est. primary completion date: July 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Persons appearing spontaneously at the consultation of parodontologie for parodontale disease,

• persons agreeing to undergo a sampling of blood intended for the search

Exclusion Criteria:

• Presence of a chronic or pointed pathology,

• an age 18-year-old subordinate or 65-year-old superior,

• pregnant women,

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Gingival Diseases
• Periodontal Disease
• Periodontal Diseases

Intervention

Other:
• Blood sampling
Analysis of the PNN, analysis of the monocytes
• Blood sampling
Analysis of the PNN, analysis of the monocytes

Locations

Country	Name	City	State
France	Hopital de la Conception- Laboratoire d'Immunologie	Marseille

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique Hopitaux De Marseille

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of positive cells and intensity of expression for the molecules of surface studied there cytometric in stream		24 months	No
Secondary	Rate of secretion of cytokines and the other substances		24 months	No
Secondary	Detection and quantification of ARN messengers		24 months	No